Table 6.
Lipid parameters with dapagliflozin in increased LDL-C and decreased LDL-C subgroup
| Increased LDL-C group (n = 20) | Decreased LDL-C group (n = 20) | p valuesb | p valuesc | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre treatment | Post treatment | % change | p valuesa | Pre treatment | Post treatment | % change | p valuesa | |||
| Total-C (mg/dL) | 188.9 ± 31.3 | 211.4 ± 43.1 | 11.9 | <0.001* | 198.4 ± 41.8 | 184.8 ± 45.8 | −6.9 | 0.002* | 0.428 | <0.0001* |
| TG (mg/dL) | 161.3 ± 69.5 | 151.6 ± 89.4 | −6.0 | 0.440 | 123.0 ± 51.8 | 114.8 ± 54.6 | −6.7 | 0.360 | 0.029* | 0.920 |
| HDL-C (mg/dL) | 45.4 ± 8.5 | 52.0 ± 9.7 | 14.5 | 0.001* | 51.5 ± 12.7 | 55.1 ± 16.0 | 7.0 | 0.070 | 0.082 | 0.242 |
| LDL-C (mg/dL) | 116.8 ± 23.0 | 133.4 ± 33.1 | 14.2 | 0.002* | 119.8 ± 40.1 | 103.5 ± 41.0 | −13.6 | <0.001* | 0.771 | <0.0001* |
| Apo AI (mg/dL) | 126.1 ± 17.8 | 140.4 ± 18.4 | 11.3 | <0.001* | 141.4 ± 22.9 | 146.8 ± 26.4 | 3.8 | 0.230 | 0.025* | 0.145 |
| Apo AII (mg/dL) | 29.5 ± 4.8 | 32.3 ± 5.1 | 9.5 | <0.001* | 29.9 ± 4.3 | 29.5 ± 4.6 | −1.3 | 0.530 | 0.798 | 0.001* |
| Apo B (mg/dL) | 100.9 ± 17.6 | 111.8 ± 22.3 | 10.8 | <0.001* | 99.3 ± 30.0 | 85.0 ± 34.7 | −14.4 | 0.014* | 0.846 | <0.0001* |
| Apo CII (mg/dL) | 4.8 ± 1.8 | 5.4 ± 2.5 | 12.5 | 0.057 | 4.7 ± 1.6 | 4.5 ± 1.8 | −4.3 | 0.270 | 0.855 | 0.029* |
| Apo CIII (mg/dL) | 10.7 ± 3.6 | 12.0 ± 4.8 | 12.1 | 0.035* | 10.2 ± 2.8 | 10.7 ± 3.8 | 4.9 | 0.340 | 0.698 | 0.240 |
| Apo E (mg/dL) | 4.3 ± 1.1 | 4.6 ± 1.7 | 7.0 | 0.280 | 4.4 ± 1.2 | 4.3 ± 1.3 | −2.3 | 0.420 | 0.904 | 0.193 |
| RLP-C (mg/dL) | 7.6 ± 5.0 | 7.8 ± 2.5 | 2.6 | 0.870 | 5.7 ± 3.3 | 5.0 ± 3.3 | −12.3 | 0.090 | 0.136 | 0.809 |
| HDL2-C (mg/dL) | 23.5 ± 5.1 | 29.1 ± 7.8 | 23.8 | <0.001* | 28.8 ± 10.03 | 32.5 ± 13.3 | 12.8 | 0.080 | 0.043* | 0.437 |
| HDL3-C (mg/dL) | 21.8 ± 4.0 | 22.8 ± 4.9 | 4.6 | 0.410 | 22.6 ± 3.6 | 22.5 ± 5.2 | −0.4 | 0.890 | 0.476 | 0.450 |
| sd LDL-C (mg/dL) | 62.0 ± 25.5 | 49.5 ± 24.5 | −20.2 | 0.048* | 46.3 ± 21.4 | 37.3 ± 23.2 | −19.4 | 0.015* | 0.046* | 0.655 |
| lb LDL-C (mg/dL) | 54.7 ± 25.3 | 83.5 ± 32.3 | 52.7 | <0.001* | 73.4 ± 27.3 | 66.1 ± 34.4 | −9.9 | 0.010* | 0.033* | <0.0001* |
| sd LDL-C/LDL-C | 0.53 ± 0.18 | 0.37 ± 0.17 | −30.2 | 0.003* | 0.38 ± 0.00 | 0.35 ± 0.17 | −7.9 | 0.250 | 0.005* | 0.021* |
Data are expressed as mean ± standard deviation or percent changes after the treatment. Clinical and laboratory parameters in the subgroup whose LDL-C was increased or decreased by dapagliflozin treatment were analyzed
Total-C total-cholesterol, TG triglycerides, HDL-C high-density lipoprotein-cholesterol, LDL-C low-density lipoprotein-cholesterol, Apo apolipoprotein, RLP-C remant-like particles-cholesterol, HDL2-C high-density lipoprotein 2-cholesterol, HDL3-C high-density lipoprotein 3-cholesterol, sd LDL-C small dense LDL-cholesterol, lb LDL-C large buoyant LDL-cholesterol
ap values for the intragroup comparison (pre vs. post treatment values in each subgroup, * p < 0.05)
bp values for intergroup comparison (increased LDL-C vs. decreased LDL-C group in the pre treatment values, * p < 0.05)
cp values for intergroup comparison (increased LDL-C vs. decreased LDL-C group in the changes from pre to post treatment, * p < 0.05)